Fenebrutinib Clinical Trials (2026): 6 Studies for Relapsing Multiple Sclerosis & Healthy Participants
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
6 Fenebrutinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Relapsing Multiple Sclerosis & Healthy Participants) and 2,611 total planned enrollment. 3 Phase 3 Fenebrutinib trials and 2 Phase 2 are listed. 1 Fenebrutinib clinical trial is actively recruiting. Most recent activity: NCT07161258 (Feb 2029).
Fenebrutinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2 | 1 | 1 | 2 | |
| P3 | 3 | 3 |
Recruiting Fenebrutinib clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07161258 | FENerations1A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) | P2 | Relapsing Multiple Sclerosis | 12 | Oct 2025 |
Fenebrutinib clinical trials by indication
Relapsing Multiple Sclerosis (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07161258 | FENerations1 | P2 | recruiting | A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) |
| NCT04586010 | FENhance | P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) |
| NCT04586023 | FENhance 2 | P3 | active not recruiting | Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) |
| NCT05119569 | FENopta | P2 | active not recruiting | A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) |
Multiple Sclerosis, Primary Progressive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04544449 | FENtrepid | P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis |
Healthy Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03596632 | — | P1 | completed | Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers |
Fenebrutinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| FENhance | NCT04586010 | P3 | active not recruiting | Relapsing Multiple Sclerosis | 746 | — |
| FENtrepid | NCT04544449 | P3 | active not recruiting | Multiple Sclerosis, Primary Progressive | 985 | — |
| FENhance 2 | NCT04586023 | P3 | active not recruiting | Relapsing Multiple Sclerosis | 751 | — |
| FENerations1 | NCT07161258 | P2 | recruiting | Relapsing Multiple Sclerosis | 12 | — |
| FENopta | NCT05119569 | P2 | active not recruiting | Relapsing Multiple Sclerosis | 109 | — |
All Fenebrutinib trials (6)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07161258 | FENerations1 | A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) | P2 | recruiting | 12 | Hoffmann-La Roche | Oct 2025 |
| NCT04586010 | FENhance | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | P3 | active not recruiting | 746 | Hoffmann-La Roche | Mar 2021 |
| NCT04544449 | FENtrepid | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | P3 | active not recruiting | 985 | Hoffmann-La Roche | Oct 2020 |
| NCT04586023 | FENhance 2 | Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | P3 | active not recruiting | 751 | Hoffmann-La Roche | Mar 2021 |
| NCT05119569 | FENopta | A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) | P2 | active not recruiting | 109 | Hoffmann-La Roche | Mar 2022 |
| NCT03596632 | Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers | P1 | completed | 8 | Hoffmann-La Roche | Jul 2018 |
Fenebrutinib clinical trials: frequently asked questions
- How many Fenebrutinib clinical trials are there?
- 6 Fenebrutinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
- Are Fenebrutinib clinical trials recruiting in 2026?
- Yes — 1 Fenebrutinib trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Fenebrutinib being studied for?
- Fenebrutinib is being studied for Relapsing Multiple Sclerosis, Healthy Participants, Multiple Sclerosis, Primary Progressive. The trials are grouped by indication on this page.
- What phase is Fenebrutinib in?
- Fenebrutinib clinical trials span 3 Phase 3, 2 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Fenebrutinib clinical trials?
- The lead sponsor across the most Fenebrutinib trials is Hoffmann-La Roche. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Fenebrutinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: